Conference Call and Webcast Scheduled for October 13, 2020, 4:30 pm ET
Read more:
Enzo Biochem to Report Fourth Quarter and Fiscal Year 2020 Financial Results on Tuesday, October 13
MONMOUTH JUNCTION, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg?for use in retinal?indications, today announced the initiation and enrollment of the first patients in its planned supplemental open-label safety study evaluating ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD) (NORSE THREE).
Patient screening begins immediately at NYU Langone Health
Read more here:
Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage
WORCESTER, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that initial Phase 1 data on MB-105, a PSCA-targeted CAR T administered systemically to patients with PSCA-positive metastatic castration-resistant prostate cancer (mCRPC), will be presented at the virtual 27th Annual Prostate Cancer Foundation Scientific Retreat, which is being held October 20 – 23, 2020.
Go here to read the rest:
Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat
SAN DIEGO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced positive topline data from an interim analysis of its Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis (GPP), also known as the GALLOP trial. GPP is a chronic, life-threatening, rare inflammatory disease with no approved therapies.
See the original post:
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
- Application Submitted for the Treatment of Partial-Onset Seizures and Migraine
See the article here:
Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)
Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth
Read this article:
GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020
Oslo, 06 October 2020
Here is the original post:
PCI Biotech: Employee share option scheme
